Components of the Quality of Life Measurement
Research type
Research Study
Full title
Components of the Quality of Life Measurement: Perspective of Patients with Metastatic Renal Cell Carcinoma
IRAS ID
311153
Contact name
Thomas Powles
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
0 years, 6 months, 2 days
Research summary
Renal cancers are common, and have drawn lots of attention from research teams to try and investigate new treatments or combinations of treatments. When testing these different treatments, it is important to get an idea of the impact of these treatments on a patient's quality of life and how taking their anti-cancer medications are affecting patients. Patients have the right to receive treatment that is effective, but also not so unpleasant that they are unable to tolerate it. Recent studies have shown that up to 50% of patients taking tyrosine kinase (TKI) based therapies have severe side effects that require treatment pauses, reductions in dose or even stopping treatment altogether. One of the ways that we try to assess how a medication or treatment is affecting a patient is getting them to fill out quality of life questionnaires. We want to gain some insight from selected patients about their opinions of the current questionnaires and how we can better improve them to represent patients more accurately.
The research will involve us asking a short series of questions about patient opinions on the current questionnaires and will end with some questions asking for suggestions for new questions or question topics we should cover in future questionnaires.
We will run through these questions in person, for example during a patient's routine clinic visit. It will consist of one session of asking these questions, and should only last approximately 30 minutes. Once we have gathered all of the data, and shared (anonymously) with other sites, patients will have the option to find out what conclusions we have drawn from everything we have gathered if they wish.
The data collected will be pseudo-anonymised.REC name
London - Bloomsbury Research Ethics Committee
REC reference
22/LO/0788
Date of REC Opinion
12 Jan 2023
REC opinion
Further Information Favourable Opinion